Nashville Biosciences
Gemma Hughes is an experienced commercial leader in the life sciences sector. Gemma is currently serving as the European Sales Director at Nashville Biosciences, where they lead the growth strategy and expansion of the company's presence in Europe. Prior to this, Gemma worked as an Advisor at Pangea.
From 2019 to 2022, Gemma held roles at Bio-Techne, starting as the North Europe Sales Manager for the Spatial Genomics Division. Gemma then became the ACD Spatial Sales Manager for France, Nordics, UK, and Ireland. Gemma is known for their results-driven approach, market understanding, and ability to address client needs.
Before joining Bio-Techne, Gemma worked at Advanced Cell Diagnostics as a Strategic Sales professional from 2018 to 2019. Gemma began their career at GATC Biotech, where they served as the Ltd Sales Manager, leading the successful launch of Europe's first commercial overnight sequencing service. Gemma also held roles as Senior Scientific Sales and Scientific Sales Representative during their tenure at GATC Biotech.
In 2007, Gemma worked as a Product Specialist at Genial Genetic Solutions. Gemma has a strong track record in solution sales, market expansion, and building high-performing teams.
Gemma Hughes completed their undergraduate education from 2002 to 2005 at the University of Liverpool, earning a Bachelor of Science (BSc) degree in Genetics.
This person is not in any offices
Nashville Biosciences
Nashville Biosciences, a wholly owned subsidiary of Vanderbilt University Medical Center, was created to harness the medical center's extensive genomic and bioinformatics resources for drug and diagnostics discovery and development. Leveraging Vanderbilt University Innovation™, Nashville Biosciences serves as a commercial interface between outside companies and the formidable research capabilities housed within Vanderbilt University Medical Center, including BioVU®, one of the world’s most comprehensive genetic databases linked to de-identified medical records with years of longitudinal clinical data. This unique asset is one of the largest and highest quality of its kind, providing an unprecedented opportunity to guide R&D activity in biotech, pharma, diagnostics, medical devices and other life sciences applications.